Fraczek Joanna, Deleu Sarah, Lukaszuk Aneta, Doktorova Tatyana, Tourwé Dirk, Geerts Albert, Vanhaecke Tamara, Vanderkerken Karin, Rogiers Vera
Department of Toxicology, Vrije Universiteit Brussel, Brussels, Belgium.
Invest New Drugs. 2009 Aug;27(4):338-46. doi: 10.1007/s10637-008-9180-x. Epub 2008 Sep 30.
The vast majority of preclinical studies of HDAC inhibitors (HDAC-I) focus on the drug-target (cancer) cell interaction, whereas little attention is paid to the effects on non-target healthy cells, which could provide decisive information to eliminate potential cytotoxic compounds at a very early stage during drug development. In the current study we used cultures of primary rat hepatocytes as a read out system to select for the most potent HDAC-I in the group of structural analogues of an archetypal HDAC-I, namely Trichostatin A. This kind of approach allowed selecting compounds with high biological activity and with no apparent toxicity towards cultured hepatocytes.
绝大多数组蛋白去乙酰化酶抑制剂(HDAC-I)的临床前研究都聚焦于药物与靶标(癌细胞)的相互作用,而对非靶标健康细胞的影响却很少关注,而这可能会在药物研发的早期阶段提供决定性信息,以剔除潜在的细胞毒性化合物。在本研究中,我们使用原代大鼠肝细胞培养物作为读出系统,从原型HDAC-I(即曲古抑菌素A)的结构类似物组中筛选出最有效的HDAC-I。这种方法能够筛选出具有高生物活性且对培养的肝细胞无明显毒性的化合物。